Bayer’s Supreme Court Victory Drives a 105% Rally — But Overbought Signals and a New Tariff Battle Divide the Analyst Community

Bayer shares surge 5.75% to near 52-week high after US Supreme Court blocks cancer warning lawsuits, but technical overbought signals and trade policy threats loom.

The speed of Bayer’s reversal has been nothing short of startling. On Thursday the stock surged 5.75% to €51.50, leaving it just 0.66% shy of its 52-week high of €51.84. That high-water mark now looks tantalisingly close, and it is easy to see why: the share price has more than doubled since hitting a 52-week low of €25.09 on 6 August 2025. The gain from that trough stands at 105.22%, while the 12-month return is 94.52% and the year-to-date advance is 35.44%.

The catalyst was the US Supreme Court’s 7-2 ruling in favour of Bayer, which held that consumers cannot sue the company for failing to include a cancer warning on glyphosate products when the Environmental Protection Agency does not require one. The decision overturned a $1.25 million verdict and effectively capped a decade-long litigation saga that had cost Bayer more than $10 billion in legal fees and settlements. Almost overnight, the market has repriced the stock, stripping out the worst-case assumptions that had weighed on the share price for years.

But the rally has pushed technical indicators deep into overbought territory. The 14-day relative strength index stood at 83.7 on Thursday, well above the 70 threshold that typically flags a looming pullback. Just a day earlier the RSI was already elevated at 80.5, underscoring how rapidly momentum has accelerated. The stock now trades 33.54% above its 50-day moving average and 39.25% above its 200-day moving average — extreme distances that are rare even for a sharp re-rating. Annualised 30-day volatility has climbed to 60.58%, making the shares behave more like a leveraged product than a blue-chip DAX heavyweight.

That technical froth is mirrored by a split among analysts. On 26 June, AlphaValue/Baader Europe downgraded Bayer to Reduce, arguing that the stock’s current price already reflects the legal relief and leaves little room for further upside. The same day, UBS reaffirmed its Buy rating and kept Bayer on its list of preferred European pharma names. Bank of America also reiterated a Buy, calling the Supreme Court decision a “big win” for the Roundup litigation. Across the major houses — BofA, DZ Bank, UBS and AlphaValue/Baader — the spectrum now runs from Buy to Reduce, with the bull camp still in the majority but the bearish voice growing louder.

Complicating the picture is a fresh trade-policy threat. The US Trade Representative is investigating German drug pricing and has scheduled a hearing for 22 September 2026. If the probe leads to retaliatory measures, the first tariffs on German pharmaceutical imports could kick in as early as 31 July 2026. The outcome remains uncertain — neither the tariff rates nor their scope have been determined — but the mere prospect adds a new layer of risk to a stock that has already absorbed years of legal uncertainty. Meanwhile, Bayer itself has opened a second front by filing a tariff complaint against Chinese glyphosate, a move designed to protect a business that has been under pricing pressure.

The combination of an overbought chart, analyst disagreement and emerging trade headwinds leaves the rally at a delicate juncture. The next major signposts are the possible imposition of tariffs from 31 July, the USTR hearing in September and Bayer’s second-quarter results in August. Those events will test whether the operating fundamentals — and the company’s ability to generate cash after years of settlement payments — can support the current valuation, or whether the more cautious assessment from AlphaValue/Baader proves prescient.

For now, the momentum is clearly with the bulls. Bayer’s market capitalisation has swelled to €46.17 billion, restoring its status as a DAX heavyweight. The Supreme Court ruling has removed the single greatest overhang, and the share price has responded in textbook fashion. But the RSI at 83.7 and the stock’s distance from its moving averages suggest a breather is likely before the €51.84 mark can be sustainably broken. The question is whether that pause turns into a deeper correction — or merely a consolidation before the next leg higher.